Role of biologics in severe eosinophilic asthma – focus on reslizumab

Role of biologics in severe eosinophilic asthma – focus on reslizumab

Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Mariaimmacolata Preianò,3 Nicola Lombardo,1 Rosa Terracciano,3 Rosario Maselli1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia&r...

Full description

Bibliographic Details
Main Authors:	Pelaia G, Vatrella A, Busceti MT, Gallelli L, Preianò M, Lombardo N, Terracciano R, Maselli R
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-07-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	IL-5 eosinophilic asthma reslizumab
Online Access:	https://www.dovepress.com/role-of-biologics-in-severe-eosinophilic-asthma-ndash-focus-on-reslizu-peer-reviewed-article-TCRM

Similar Items

Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
by: Pérez de Llano LA, et al.
Published: (2022-01-01)

Reslizumab in the management of poorly controlled asthma: the data so far
by: Maselli DJ, et al.
Published: (2016-08-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017-10-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Successful treatment of refractory eosinophilic fasciitis with reslizumab
by: Mahta Mortezavi, MD, et al.
Published: (2020-09-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2019-12-01)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
by: Drick N, et al.
Published: (2020-11-01)

Successful induction treatment of bullous pemphigoid using reslizumab: a case report
by: Hyo-In Rhyou, et al.
Published: (2021-11-01)

Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma
by: A S Kolbin, et al.
Published: (2019-12-01)

Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
by: Sahota J, et al.
Published: (2018-05-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020-10-01)

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
by: Daniel P. Henriksen, et al.
Published: (2018-01-01)

The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
by: H. Ibrahim, et al.
Published: (2019-12-01)

Severe eosinophilic asthma: therapeutic potential of Reslizumab
by: R. S. Fassakhov
Published: (2018-10-01)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
by: Pelaia C, et al.
Published: (2018-03-01)

Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives
by: Padilla Galo A, et al.
Published: (2018-08-01)

Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis
by: Milosavljević Miloš N., et al.
Published: (2018-01-01)

MONOCLONAL ANTIBODY-BASED THERAPY FOR EOSINOPHILIC OESOPHAGITIS
by: Garry Walsh
Published: (2016-12-01)

Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief
by: Oliver William Massey, et al.
Published: (2022-09-01)

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
by: Andrea Matucci, et al.
Published: (2018-08-01)

Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
by: Wen Li, et al.
Published: (2024-02-01)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
by: Alessandro Vatrella, et al.
Published: (2022-09-01)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
by: Menzella F, et al.
Published: (2021-02-01)

Nonepisodic angioedema with eosinophilia after COVID-19 vaccination: a case successfully treated with reslizumab
by: Young-Hee Nam
Published: (2023-02-01)

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV1 reversibility
by: J. Christian Virchow, et al.
Published: (2020-04-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
by: Haldar P
Published: (2017-06-01)

Evidence-Based Approach of Biologic Therapy in Bronchial Asthma
by: Adnan Liaqat, et al.
Published: (2023-06-01)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
by: Pelaia C, et al.
Published: (2021-02-01)

Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons
by: Musaddique Hussain, et al.
Published: (2024-02-01)

Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?
by: Glenn Van Hulst, et al.
Published: (2021-09-01)

Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma
by: Manuel J. Rial, et al.
Published: (2021-03-01)

Molecular Targets for Biological Therapies of Severe Asthma
by: Corrado Pelaia, et al.
Published: (2020-11-01)

Bronchial asthma and interleukin-5
by: Das Undurti, et al.
Published: (2001-02-01)

Elaborate biologic approval process delays care of patients with moderate-to-severe asthma
by: Esha Sehanobish, PhD, et al.
Published: (2023-05-01)

Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma
by: Virginija Kalinauskaite-Zukauske, et al.
Published: (2019-08-01)

Fasting impairs type 2 helper T cell infiltration in the lung of an eosinophilic asthma mouse model
by: Yusuke Suzuki, et al.
Published: (2021-09-01)

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients
by: Maged Mohamed Refaat, et al.
Published: (2022-10-01)

Korean Adolescent Patient with Manifestations of Lymphocyte Variant Hypereosinophilic Syndrome and Episodic Angioedema with Eosinophilia, Treated with Reslizumab
by: Jie Hee Jue, et al.
Published: (2022-04-01)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
by: Corrado Pelaia, et al.
Published: (2022-06-01)

Interleukin-13 in Asthma and Other Eosinophilic Disorders
by: Emma Doran, et al.
Published: (2017-09-01)